Kennedy praised Operation Warp Speed as an achievement while emphasizing that he was supportive of Trump’s backing for non-vaccine therapeutics ... houses many drug companies, including Moderna, maker ...

CRISPR Therapeutics AG (CRSP) stock jumped over 9% this week after delivering strong Q4 2024 results ahead of schedule. The ...

Reports fourth quarter revenues of $1.0 billion, GAAP net loss of $(1.1) billion and GAAP EPS of $(2.91); loss includes approximately $0.2 ...

Dr. Gehchan brings decades of successful late-stage clinical development and commercial experience to role, further enhancing Kyverna's senior leadership team to execute Company's next wave of ...

Moderna provides updates on its business and ... three regulatory filings seeking the FDA’s approval. Intellia Therapeutics announced its strategic priorities and key anticipated milestones ...

Stocks recently featured in the blog include: Amgen AMGN, CRISPR Therapeutics CRSP, Moderna MRNA, Sarepta Therapeutics SRPT and Vertex Pharmaceuticals VRTX. Here are highlights from Wednesday’s ...

Roche Holding AG Akt-0.56% CHF240.64B ...

Moderna is a stock that deserves a closer look. The company still has several fundamental strong points, including an extensive pipeline of therapeutics in clinical trials that could be the ...

A new storage technique can keep protein-based drugs and vaccines stable without keeping them cold. The discovery, led by researchers at Penn State, could eliminate the need for refrigeration for ...

We expect Moderna MRNA to surpass expectations when ... combination of elements to beat onearnings this time around: CRISPR Therapeutics CRSP has an Earnings ESP of +8.09% and a Zacks Rank ...